Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan;127(1):119-121.
doi: 10.1016/j.ophtha.2019.07.025.

Retinal Imaging in Alzheimer's Disease: In Search of the Holy Grail

Amani A Fawzi, Sandra Weintraub, Waleed Fawzi
Editorial

Retinal Imaging in Alzheimer's Disease: In Search of the Holy Grail

Amani A Fawzi et al. Ophthalmology. 2020 Jan.
No abstract available

PubMed Disclaimer

Figures

None
Pembrolizumab-Related Enophthalmos
Pembrolizumab is a highly selective immune checkpoint inhibitor that targets the programmed cell death protein (PD-1) receptor on lymphocytes and has been approved for the treatment of malignant melanoma. A 59-year-old woman had been treated for 1 year with pembrolizumab for melanoma metastatic to lung, spleen, and central nervous system. She noted changes of her facial appearance with temporal wasting and sunken eyes while denying any decrease in body weight. Exophthalmometry was 11 mm for the right eye (OD) and 10 mm for the left eye (OS). (Fig A, B) Axial magnetic resonance imaging (MRI) scans performed 6 months apart (Fig C, D) demonstrated a significant change in globe position with 4.7 mm recession on the right and 4.1 mm on the left. There were no signs of orbital metastasis or inflammation. She had no other medical or iatrogenic factors to explain loss of orbital volume and enophthalmos. (Magnified version of Fig A-D is available online at www.aaojournal.org).
See this image and copyright information in PMC

Comment on

References

    1. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14(3):367–429. - PubMed
    1. Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6(4):1–7. - PMC - PubMed
    1. Khan TK. An algorithm for preclinical diagnosis of Alzheimer’s disease. Front Neurosci 2018;12:275. - PMC - PubMed
    1. Ito Y, Sasaki M, Takahashi H, et al. Quantitative assessment of the retina using OCT and associations with cognitive function. Ophthalmology 2019;127:107–118. - PubMed
    1. Blanks JC, Hinton DR, Sadun AA, Miller CA. Retinal ganglion cell degeneration in Alzheimer’s disease. Brain Res 1989;501(2):364–372. - PubMed